<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CHIRHOSTIM- secretin humanÂ injection, powder, lyophilized, for solutionÂ </strong><br>ChiRhoClin, Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Dosage and Administration <a href="#Section_2.0">(2.0)</a> 06/2007 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ChiRhoStim<span class="Sup">Â®</span> is indicated for:  </p>
<ul>
<li>Stimulation of pancreatic secretions, including <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> to aid in the diagnosis of exocrine pancreas dysfunction <a href="#Section_1.1">(1.1)</a>
</li>
<li>Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma (<a href="#Section_1.2">1.2</a>)</li>
<li>Facilitation of identification of the ampulla of Vater and the accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP)  <a href="#Section_1.3">(1.3)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Stimulation of pancreatic secretions, including <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> to aid in the diagnosis of exocrine pancreas dysfunction <a href="#Section_2.1">(2.1)</a></span> </p>
<ul><li>0.2 mcg/kg body weight by intravenous injection over 1 minute.</li></ul>
<p class="Highlighta"><span class="Bold">Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma  <a href="#Section_2.2">(2.2)</a></span> </p>
<ul><li>0.4 mcg/kg body weight by intravenous injection over 1 minute.</li></ul>
<p class="Highlighta"><span class="Bold">Facilitation of identification of the ampulla of Vater and the accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP) <a href="#Section_2.3">(2.3)</a></span> </p>
<ul><li>0.2 mcg/kg body weight by intravenous injection over 1 minute.</li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">ChiRhoStim<span class="Sup">Â®</span> is available in two strengths: </p>
<ul class="Disc">
<li>As a lyophilized sterile powder in 10 mL vials containing 16 mcg of human secretin.  Reconstitute with 8 mL of saline for injection to yield a final concentration of 2 mcg of human secretin/mL <a href="#Section_3.1">(3.1)</a>
</li>
<li>As a lyophilized sterile powder in 10 mL vials containing 40 mcg of human secretin.  Reconstitute with 10 mL of saline for injection to yield final concentration of 4 mcg of human secretin /mL <a href="#Section_3.2">(3.2)</a>
</li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients suffering from <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> should not receive ChiRhoStim<span class="Sup">Â®</span> until the acute episode has subsided <a href="#Section_4">(4)</a>. </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> <a href="#Section_5.1">(5.1)</a>.</li>
<li>Vagotomy or <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory Bowel Disease</span> <a href="#Section_5.2">(5.2)</a>.</li>
<li>Alcoholic or Other Liver Disease <a href="#Section_5.3">(5.3)</a>.</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions (&gt;0.5%) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <a href="#Section_6">(6)</a>. </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">The concomitant use of anticholinergic agents may make patients hyporesponsive, i.e., may produce a false result <a href="#Section_7">(7)</a>.  Results of secretin testing in these patients should be interpreted with caution. </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">The safety evaluation of ChiRhoStim<span class="Sup">Â®</span> in geriatric patients showed no difference from the safety evaluation in the general population   (<a href="#section-9">9</a>)</p></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2007</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-2.1" class="toc">1.1  Stimulation of pancreatic secretions, including <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, to aid in the diagnosis of pancreatic exocrine dysfunction,</a></h2>
<h2><a href="#section-2.2" class="toc">1.2	Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and</a></h2>
<h2><a href="#section-2.3" class="toc">1.3  Facilitation of the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP).</a></h2>
<h1><a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-3.1" class="toc">2.1 Stimulation of Pancreatic Secretions, Including <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> to Aid in the Diagnosis of Exocrine Pancreas Dysfunction:</a></h2>
<h2><a href="#section-3.2" class="toc">2.2	Stimulation of Gastrin Secretion to Aid in Diagnosis of Gastrinoma: </a></h2>
<h2><a href="#section-3.3" class="toc">2.3	Facilitation of the Identification of the Ampulla of Vater and Accessory Papilla During Endoscopic Retrograde Cholangiopancreatography (ERCP) to aid in cannulation of the pancreatic duct: </a></h2>
<h2><a href="#section-3.4" class="toc">2.4	ADMINISTRATION </a></h2>
<h1><a href="#section-4" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h2><a href="#section-4.1" class="toc"></a></h2>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-6.2" class="toc">5.2	Vagotomy or <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory Bowel Disease</span></a></h2>
<h2><a href="#section-6.3" class="toc">5.3	Alcoholic or Other Liver Disease</a></h2>
<h1><a href="#section-7" class="toc">6	ADVERSE REACTIONS</a></h1>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-9" class="toc">8  USE IN SPECIAL POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-9.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-9.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2	Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Stimulation of pancreatic secretions, including <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> to aid in the diagnosis of Exocrine Pancreas Dysfunction:</a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma </a></h2>
<h2><a href="#section-13.3" class="toc">14.3	Facilitation of identification of the ampulla of Vater and the accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP) to assist in cannulation of the pancreatic ducts </a></h2>
<h1><a href="#section-14" class="toc">15	REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage</a></h2>
<h1><a href="#section-16" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ChiRhoStim<span class="Sup">Â®</span> is indicated for: </p>
<div class="Section">
<a name="Section_1.1"></a><a name="section-2.1"></a><p></p>
<h2>1.1  Stimulation of pancreatic secretions, including <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, to aid in the diagnosis of pancreatic exocrine dysfunction,</h2>
<p class="First"></p>
</div>
<div class="Section">
<a name="Section_1.2"></a><a name="section-2.2"></a><p></p>
<h2>1.2	Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and</h2>
<p class="First"></p>
</div>
<div class="Section">
<a name="Section_1.3"></a><a name="section-2.3"></a><p></p>
<h2>1.3  Facilitation of the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP).</h2>
<p class="First"></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-3"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<div class="Section">
<a name="Section_2.1"></a><a name="section-3.1"></a><p></p>
<h2>2.1 Stimulation of Pancreatic Secretions, Including <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> to Aid in the Diagnosis of Exocrine Pancreas Dysfunction:</h2>
<p class="First">0.2 mcg/kg body weight by intravenous injection over 1 minute.</p>
<p><span class="Underline">Gastroduodenal (Dreiling) Tube Collection Method</span><span class="Sup">(1)</span>:</p>
<p>A radiopaque, double-lumen tube is passed through the mouth following a 12-15 hour fast.  Under fluoroscopic control, the opening of the proximal lumen of the tube is placed in the gastric antrum and the opening of the distal lumen just beyond the papilla of Vater.  The positioning of the tube must be confirmed and the tube secured prior to synthetic human secretin testing.  Intermittent negative pressure of 25-40 mmHg is applied to both lumens and maintained throughout the test.  When duodenal contents have a pH of â‰¥ 6, a baseline sample of duodenal fluids is collected for a 10 minute period.  A test dose of ChiRhoStim<span class="Sup">Â®</span>  0.2 mcg if using the 16 mcg vial (0.1 mL) or 0.4 mcg if using the 40 mcg vial (0.1 mL) is injected intravenously to test for possible allergies.  After one minute, if there are no signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, ChiRhoStim<span class="Sup">Â®</span> at a dose of 0.2 mcg/kg of body weight is injected intravenously over 1 minute.  Duodenal fluid is collected for 60 minutes thereafter.  The aspirate is divided into four collection periods of fifteen minutes each.  The duodenal lumen of the tube is cleared with an injection of air after collection of each sample.  Wide variation in volume of the aspirate is indicative of incomplete <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>.  Each sample of duodenal fluid is to be chilled and subsequently analyzed for volume and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> concentration.  Exocrine pancreas dysfunction typically associated with <span class="product-label-link" type="condition" conceptid="195596" conceptname="Chronic pancreatitis">chronic pancreatitis</span> is indicated if the peak <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> concentration for any sample â‰¤ 80 mEq/L.</p>
<p><span class="Underline">Endoscopic Collection Method: Endoscopic Pancreatic Function Test (ePFT)</span><span class="Sup">(2-4)</span>:</p>
<p>After assessment of patients for sedation and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, a test dose of ChiRhoStim<span class="Sup">Â®</span> 0.2 mcg if using the 16 mcg vial (0.1 mL) or 0.4 mcg if using the 40 mcg vial (0.1 mL) is injected intravenously to test for possible allergies.   After one minute, if there are no signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, ChiRhoStim<span class="Sup">Â®</span> at a dose of 0.2 mcg/kg of body weight is injected intravenously over 1 minute. An upper endoscopy is performed with conscious sedation, after topical anesthetic.  All gastric fluid is aspirated through the endoscope and discarded.  After small bowel intubation to the junction of the second and third portion of the duodenum, fluid is aspirated for 1 to 3 minutes and collected in 5 separate specimen traps at baseline (0), 15, 30, 45, and 60 minutes after secretin injection.  The patients remain intubated with the upper endoscope for one hour in the left lateral <span class="product-label-link" type="condition" conceptid="4127794" conceptname="Decubitus">decubitus</span> position.  Boluses of meperidine and midazolam in a 25:1 mg ratio are administered to maintain <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and sedation during the 1-hour procedure.  Each sample of duodenal fluid is to be chilled and subsequently analyzed for volume and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> concentration.  Exocrine pancreas dysfunction typically associated with <span class="product-label-link" type="condition" conceptid="195596" conceptname="Chronic pancreatitis">chronic pancreatitis</span> is indicated if the peak <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> concentration for any sample â‰¤ 80 mEq/L.</p>
</div>
<div class="Section">
<a name="Section_2.2"></a><a name="section-3.2"></a><p></p>
<h2>2.2	Stimulation of Gastrin Secretion to Aid in Diagnosis of Gastrinoma: </h2>
<p class="First">0.4 mcg/kg body weight by intravenous injection over 1 minute.</p>
<p>The patient should fast for at least 12 hours prior to beginning the test.  Prior to injection of ChiRhoStimÂ®, two blood samples are drawn for determination of fasting serum gastrin levels (baseline values).  Subsequently, a test dose of ChiRhoStim<span class="Sup">Â®</span> 0.2 mcg if using the 16 mcg vial (0.1 mL) or 0.4 mcg if using the 40 mcg vial (0.1 mL) is injected intravenously to test for possible allergies.  If there are no signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, ChiRhoStim<span class="Sup">Â®</span> at a dose of 0.4 mcg/kg of body weight is injected intravenously over 1 minute; post-injection blood samples are collected after 1, 2, 5, 10, and 30 minutes for determination of serum gastrin concentrations.</p>
<p>Gastrinoma is strongly indicated in patients who show an increase in serum gastrin concentrations of 110 pg/mL over basal level on any of the post injection samples.</p>
</div>
<div class="Section">
<a name="Section_2.3"></a><a name="section-3.3"></a><p></p>
<h2>2.3	Facilitation of the Identification of the Ampulla of Vater and Accessory Papilla During Endoscopic Retrograde Cholangiopancreatography (ERCP) to aid in cannulation of the pancreatic duct: </h2>
<p class="First">0.2 mcg/kg body weight by intravenous injection over 1 minute.</p>
<p>Administration of ChiRhoStim<span class="Sup">Â®</span> may be given when difficulty is encountered by the endoscopist in identifying the ampulla of Vater for various reasons including: anatomic <span class="product-label-link" type="condition" conceptid="4168498" conceptname="Deformity">deformity</span> secondary to prior surgery, radiation therapy, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span>, tumors, etc. or in identifying the accessory papilla in patients with pancreas divisum. A test dose of ChiRhoStim<span class="Sup">Â®</span> 0.2 mcg if using the 16 mcg vial (0.1 mL) or 0.4 mcg if using the 40 mcg vial (0.1 mL) is injected intravenously to test for possible allergies.  If there are no signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, a dose of 0.2 mcg/kg of body weight intravenously over 1 minute may be administered and will result in visible excretion of pancreatic fluid from the orifices of these papillae enabling their identification and facilitating their cannulation.</p>
</div>
<div class="Section">
<a name="Section_2.4"></a><a name="section-3.4"></a><p></p>
<h2>2.4	ADMINISTRATION </h2>
<p class="First">ChiRhoStim<span class="Sup">Â®</span> 16 mcg vial:<br>Dissolve the contents of the ChiRhoStimÂ® 16 mcg vial in <span class="Underline">8 mL</span> of Sodium Chloride Injection USP, to yield a concentration of <span class="Underline">2 mcg/mL</span>. Shake vigorously to ensure dissolution.  Use immediately after reconstitution and discard any unused portion.</p>
<p>ChiRhoStim<span class="Sup">Â®</span> 40 mcg vial:<br>Dissolve the contents of the ChiRhoStim<span class="Sup">Â®</span> 40 mcg vial in <span class="Underline">10 mL</span> of Sodium Chloride Injection USP, to yield a concentration of <span class="Underline">4 mcg/mL</span>.  Shake vigorously to ensure dissolution.  Use immediately after reconstitution and discard any unused portion. </p>
<p>For both strengths, the reconstituted drug product should be inspected visually prior to administration.  If particulate matter or discoloration is seen, the product should be discarded.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-4"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<div class="Section">
<a name="section-4.1"></a><p></p>
<h2></h2>
<p class="First">ChiRhoStim<span class="Sup">Â®</span> is available in two strengths:</p>
<p><span class="Bold">As a lyophilized sterile powder in 10 mL vials containing 16 mcg of human secretin.</span></p>
<p><span class="Bold">As a lyophilized sterile powder in 10 mL vials containing 40 mcg of human secretin.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section">
<a name="Section_4.1"></a><a name="section-5.1"></a><p></p>
<p class="First">Patients suffering from <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> should not receive ChiRhoStim<span class="Sup">Â®</span> until the acute episode has subsided.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section">
<a name="Section_5.1"></a><a name="section-6.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">	Because of a potential <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ChiRhoStim<span class="Sup">Â®</span> patients should receive an intravenous test dose of 0.1 mL of the respective reconstituted vial.  If no signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> are noted after one minute, the recommended dose may be injected slowly over 1 minute.  A test dose is especially important in patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> and/or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.  Appropriate measures for the treatment of acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> should be immediately available.  No <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> were observed after the test dose or full dose of synthetic human secretin in 584 patients and volunteers.</p>
</div>
<div class="Section">
<a name="Section_5.2"></a><a name="section-6.2"></a><p></p>
<h2>5.2	Vagotomy or <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory Bowel Disease</span></h2>
<p class="First">Patients who have undergone vagotomy or who have <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> may be hyporesponsive to secretin stimulation.  This response does not indicate pancreatic disease, and results of secretin stimulation tests in these patients should be interpreted with caution.</p>
</div>
<div class="Section">
<a name="Section_5.3"></a><a name="section-6.3"></a><p></p>
<h2>5.3	Alcoholic or Other Liver Disease</h2>
<p class="First">A greater than normal volume response to secretin stimulation, which may mask coexisting pancreatic disease, is occasionally encountered in patients with alcoholic or other liver disease.  Results of secretin stimulation tests in these patients should thus be interpreted with caution.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-7"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6.1"></a><a name="section-7.1"></a><p></p>
<p class="First">Mild to moderate adverse reactions have been noted for synthetic human secretin in clinical studies in 533 patients and 51 healthy volunteers.  Two severe adverse reactions, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, occurred in one patient.  Table 1 details the type and number of patients with adverse reactions.</p>
<table width="100%">
<caption><span>TABLE 1   ADVERSE REACTIONS WITH CHIRHOSTIM<span class="Sup">Â®</span></span></caption>
<colgroup>
<col width="30%">
<col width="70%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="left">Adverse Reaction</th>
<th class="Botrule Rrule" align="center">N = 584<br>Incidence<br>(Patients)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center">11 (11)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>	</td>
<td class="Botrule Rrule" align="center">4 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Early removal of Dreiling tube	</td>
<td class="Botrule Rrule" align="center">3 (3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>	</td>
<td class="Botrule Rrule" align="center">3 (3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>	</td>
<td class="Botrule Rrule" align="center">3 (3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Increased heart rate	</td>
<td class="Botrule Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Mild <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></td>
<td class="Botrule Rrule" align="center">	2 (2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">Upset stomach</span>	</td>
<td class="Botrule Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Burning in stomach or abdomen	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">Clammy</span> skin	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Decreased O<span class="Sub">2</span> saturation	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Faintness	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Infiltrated IV	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Oral secretions increased	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Sedation	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Slow heart rate (57bpm)	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Tingling</span> in legs	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Unresponsive	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Warm sensation in abdomen	</td>
<td class="Botrule Rrule" align="center">1 (1)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Warm sensation in face	</td>
<td class="Rrule" align="center">1 (1)</td>
</tr>
</tbody>
</table>
<p>Of the 584 patients and healthy volunteers treated with ChiRhoStim<span class="Sup">Â®</span>, a total of 29 patients (5%) had at least one adverse reaction.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">The concomitant use of anticholinergic agents may make patients hyporesponsive to secretin stimulation and may produce a false result.  Any results of secretin stimulation tests in these patients should thus be interpreted with caution. </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-9"></a><p></p>
<h1>8  USE IN SPECIAL POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">	Animal reproduction studies have not been conducted with synthetic human secretin.  It is also not known whether synthetic human secretin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Synthetic human secretin should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-9.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether synthetic human secretin is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when synthetic human secretin is administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-9.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">	Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-9.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">	Among the 533 patients who have received ChiRhoStim<span class="Sup">Â®</span> in clinical trials 18% were 65 years of age or older and 6% were 75 years of age or older.  Dosing was the same as that for the overall population of patients.  No overall differences in safety, pharmacologic response, or diagnostic effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and the younger patients, but greater sensitivity of some older individuals to ChiRhoStim<span class="Sup">Â®</span> cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<div class="Section">
<a name="section-10.1"></a><p></p>
<p class="First">Human secretin is a gastrointestinal peptide hormone produced by cells in the duodenum in response to acidification.  ChiRhoStim<span class="Sup">Â®</span> (human secretin as the acetate) is a purified synthetic peptide with an amino acid sequence identical to the naturally occurring hormone.  Synthetic human secretin is chemically defined as follows:</p>
<p>Molecular Weight 3039.44<br>
Empirical Formula: C<span class="Sub">130</span>H<span class="Sub">220</span>N<span class="Sub">44</span>O<span class="Sub">39</span><br>
CAS # 108153-74-8</p>
<p>Structural Formula:<br>
His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH<span class="Sub">2</span></p>
<p>ChiRhoStim<span class="Sup">Â®</span> is available in two strengths:</p>
<p>As a 10 ml vial which contains 16 mcg of purified synthetic human secretin, 1.5 mg of L-cysteine hydrochloride, 20 mg of mannitol, and 9 mg of sodium chloride per vial.  When reconstituted in <span class="Bold">8 mL</span> of Sodium Chloride Injection USP, each mL of solution contains <span class="Bold">2 mcg</span> synthetic human secretin for intravenous use.  The pH of the reconstituted solution has a range of 3 to 6.5. </p>
<p>As a 10 ml vial which contains 40 mcg of purified synthetic human secretin, 3.75 mg of L-cysteine hydrochloride, 50 mg of mannitol, and 22.5 mg of sodium chloride per vial.  When reconstituted in <span class="Bold">10 mL</span> of Sodium Chloride Injection USP, each mL of solution contains <span class="Bold">4 mcg</span> synthetic human secretin for intravenous use.  The pH of the reconstituted solution has a range of 3 to 6.5.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First">	The primary action of ChiRhoStim<span class="Sup">Â®</span> is to increase the volume and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> content of secreted pancreatic juices. The standard unit of activity used for ChiRhoStim<span class="Sup">Â®</span> is the clinical unit as defined in the literature.<span class="Sup">(5)</span>  Synthetic human secretin (sHS), synthetic porcine secretin (sPS) and biologically derived porcine secretin (bPS) have been evaluated and compared in the validated cat bioassay used for release of bPS.  sHS and sPS were found to have similar pharmacological activity in terms of stimulating the exocrine pancreas to secrete juice and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.  The potency correlation with bPS for both sHS and sPS was 0.2 mcg (sHS or sPS) corresponding to 1 CU (bPS).  The biological activity of sHS and sPS was approximately 5.0 CU per mcg as opposed to 3.0 CU per mcg for bPS.   </p>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_121"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Secretin is a hormone that is normally released from the duodenum upon exposure of the proximal intestinal lumen to gastric acid, fatty acids and amino acids. Secretin is released from enterochromaffin cells in the intestinal mucosa. Secretin receptors have been identified in the pancreas, stomach, liver, colon and other tissues. When secretin binds to secretin receptors on pancreatic duct cells it opens <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> transmembrane conductance regulator (CFTR) channels, leading to secretion of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>-rich-pancreatic fluid. Secretin may also work through vagal-vagal neural pathways since stimulation of the efferent vagus nerve stimulates <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> secretion and atropine blocks secretin-stimulated pancreatic secretion. See references 6 and 7 for additional details on mechanism of action of secretin and feedback controls.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The PK profile for synthetic human secretin was evaluated in 12 normal subjects. After intravenous bolus administration of 0.4 mcg/kg, synthetic human secretin concentration rapidly declines to baseline secretin levels within 90 to 120 minutes. The elimination half-life of synthetic human secretin is 45 minutes. The clearance of synthetic human secretin is 580.9 Â± 51.3 mL/min and the volume of distribution is 2.7 L. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the carcinogenic potential of synthetic human secretin.  Studies to evaluate the potential for impairment of fertility or mutagenicity of synthetic human secretin have not been performed.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="Section_13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2	Animal Toxicology and/or Pharmacology</h2>
<p class="First">A single intravenous dose of synthetic human secretin at 20 mcg/kg was not lethal to mice or rabbits.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Stimulation of pancreatic secretions, including <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> to aid in the diagnosis of Exocrine Pancreas Dysfunction:</h2>
<p class="First">ChiRhoStim<span class="Sup">Â®</span> administered intravenously stimulates the exocrine pancreas to secrete pancreatic juice, which can assist in the diagnosis of exocrine pancreas dysfunction.  Normal ranges for pancreatic secretory response to intravenous secretin in patients with defined pancreatic disease have been shown to vary.  One source of variation is related to the inter-investigator differences in operative technique.</p>
<p>In two crossover studies (CRC98-2 and CRC99-9), a total of 18 patients with a documented history of <span class="product-label-link" type="condition" conceptid="195596" conceptname="Chronic pancreatitis">chronic pancreatitis</span> were given sHS, sPS and bPS.  The results appear in Figures 1 and 2.  In another study, 35 normal volunteers were given sHS.  The results appear in Figures 1 and 2.</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd&amp;name=chirhostim-fig1.jpg"></div>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd&amp;name=chirhostim-fig2.jpg"></div>
<p>The values obtained for Figures 1 and 2 were performed by investigators skilled in performing secretin stimulation testing and are to be taken only as guidelines.  These results should not be generalized to results of secretin stimulation testing conducted in other laboratories.  However, a volume response of less than 2 mL/kg/hr, <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> concentration of less than 80 mEq/L, and a <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> output of less than 0.2 mEq/kg/hr are consistent with impaired pancreatic function.</p>
<p>A physician or institution planning to perform secretin stimulation testing as an aid to the diagnosis of pancreatic disease should begin by assessing enough normal subjects (&gt;5) to develop proficiency in proper techniques and to generate normal response ranges for the commonly assessed parameters for pancreatic exocrine response to ChiRhoStim<span class="Sup">Â®</span>.</p>
<p>In three crossover studies (CRC 98-1, CRC 98-2, and CRC 99-9) evaluating 21 different patients with a documented history of <span class="product-label-link" type="condition" conceptid="195596" conceptname="Chronic pancreatitis">chronic pancreatitis</span>, synthetic human secretin (sHS) was compared to synthetic porcine secretin (sPS) and biologically derived secretin (bPS).  All of the patients treated with these drugs had peak <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> concentrations of &lt; 80 mEq/L.</p>
<p>Pancreatic secretory response to intravenous synthetic human secretin in 35 normal healthy subjects demonstrated a mean peak <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> concentration of 100 mEq/L and a mean total volume over one hour of 260.7 mL.  All 35 subjects had peak <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> concentrations â‰¥ 80 mEq/L.</p>
</div>
<div class="Section">
<a name="Section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma </h2>
<p class="First">ChiRhoStim<span class="Sup">Â®</span> administered intravenously stimulates gastrin release in patients with gastrinoma (Zollinger-Ellison Syndrome), whereas no or only small changes in serum gastrin concentrations occur in normal subjects and in patients with <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease.  Deveney, et al. established the high sensitivity and specificity of the secretin stimulation test to aid in the diagnosis of gastrinoma and found using discriminant analysis that an increase from baseline of â‰¥ 110 pg/mL was the optimal point separating positive and negative tests.<span class="Sup">(8)</span>  This gastrin response is the basis for the use of synthetic human secretin as a provocative test in the evaluation of patients in whom gastrinoma is a diagnostic consideration.</p>
<p>In a three way crossover study of 6 patients with tissue diagnosed gastrinoma, there was agreement among synthetic human secretin (ChiRhoStim<span class="Sup">Â®</span>), synthetic porcine secretin and biologically derived porcine secretin regarding gastrin levels. Serum gastrin levels were reported to be &gt;110 pg/mL for all secretin products tested after stimulation with 0.4 mcg/kg secretin.  Testing of ChiRhoStim<span class="Sup">Â®</span> in 12 healthy volunteers demonstrated completely negative results for gastrinoma.</p>
</div>
<div class="Section">
<a name="Section_14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3	Facilitation of identification of the ampulla of Vater and the accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP) to assist in cannulation of the pancreatic ducts </h2>
<p class="First">In a randomized, placebo controlled crossover study in 24 patients with pancreas divisum undergoing ERCP, synthetic human secretin administration at a dose of 0.2 mcg/kg resulted in 16 of 24 successful cannulations of the minor duct compared to 2 of 24 for placebo. </p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_15"></a><a name="section-14"></a><p></p>
<h1>15	REFERENCES</h1>
<div class="Section">
<a name="section-14.1"></a><p></p>
<ol class="Arabic">
<li> Dreiling DA.  Pancreatic secretory testing in 1974. Gut. 1975;16(8):653-7.</li>
<li> Stevens T, Conwell DL, Zuccaro G Jr, Van Lente F, Purich E, Khandwala F, Fein S. A randomized crossover study of secretin-stimulated endoscopic and dreiling tube pancreatic function test methods in healthy subjects. Am J Gastroenterol. 2006 Feb;101(2):351-5.</li>
<li>Yadav D, Chari ST. The Endoscopic Pancreatic Exocrine Function Test (ePFT): Can it be the New â€œGold Standardâ€?? Gastroenterology 2006 Oct;131(4):1349-1350.</li>
<li>	Conwell DL, Zuccaro G, Purich E, Fein S, Vanlente F, Vargo J, Dumot J, O'laughlin C, Trolli P. The effect of moderate sedation on exocrine pancreas function in normal healthy subjects: a prospective, randomized, cross-over trial using the synthetic porcine secretin stimulated Endoscopic Pancreatic Function Test (ePFT). Am J Gastroenterol. 2005 May;(5):1161-6.</li>
<li>Jorpes, E. and Mutt V. On the biological assay of secretin. The reference standard. Acta Physiol Scand. 1966 Mar;66(3):316-25.</li>
<li>	Chey WY, Chang T-M, Secretin. In: Kasin AJ. Editor. Handbook of Biologically Active Peptides. Elsevier, Amsterdam. 2006;1115-1122.</li>
<li>	Whitcomb DC. Neurohormonal Control of the Exocrine Pancreas. In:Greeley JR G, editor. Endocrinology of the Gastrointestinal System. Totowa NJ:Humana Press. 1998;239-258.</li>
<li>	Deveney, C.W., et al. Use of Calcium and Secretin in the Diagnosis of Gastrinoma (Zollinger-Ellison Syndrome). Ann Intern Med. 1977 Dec;87(6):680-6.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="Section_16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<dl>
<dt>Â </dt>
<dd>ChiRhoStim <span class="Sup">Â®</span> 16 mcg vial NDC # 67066-005-01</dd>
<dt>Â </dt>
<dd>ChiRhoStim <span class="Sup">Â®</span>40 mcg vial NDC # 67066-007-01</dd>
</dl>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16.1"></a><a name="section-15.1"></a><p></p>
<h2>16.1 Supplied</h2>
<p class="First"><span class="Bold">ChiRhoStim<span class="Sup">Â®</span> is supplied in two strengths:</span></p>
<p>As a lyophilized sterile powder in vials containing 16 mcg of human secretin.</p>
<p>As a lyophilized sterile powder in vials containing 40 mcg of human secretin.  </p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="Section_16.2"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">The unreconstituted product should be stored at -20Â°C (freezer).  Expiration date is marked on the label.  Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-16"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Since there is no data on pregnant or nursing mothers, physicians should discuss these matters with the patient before using this product.</p>
<p>ChiRhoStim<span class="Sup">Â®</span> is a registered trademark of ChiRhoClin, Inc.</p>
<p>Manufactured for: <br>
ChiRhoClin, Inc<br>
Burtonsville, MD 20866-6129</p>
<p>Manufactured by:<br>
Bell-More Labs, Inc. <br>
Hampstead, Maryland 21074-0179</p>
<p>005PI504</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CHIRHOSTIMÂ 		
					</strong><br><span class="contentTableReg">secretin human injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67066-005</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Secretin human</strong> (Secretin human) </td>
<td class="formItem"></td>
<td class="formItem">16Â ug Â inÂ 8Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>L-cysteine hydrochloride</strong></td>
<td class="formItem">1.5Â mg Â inÂ 8Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">20Â mg Â inÂ 8Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride </strong></td>
<td class="formItem">9Â mg Â inÂ 8Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67066-005-01</td>
<td class="formItem">8 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CHIRHOSTIMÂ 		
					</strong><br><span class="contentTableReg">secretin human injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67066-007</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Secretin human</strong> (Secretin human) </td>
<td class="formItem"></td>
<td class="formItem">40Â ug Â inÂ 10Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>L-cysteine hydrochloride</strong></td>
<td class="formItem">3.75 Â mg Â inÂ 10Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">50Â mg Â inÂ 10Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride </strong></td>
<td class="formItem">22.5Â mg Â inÂ 10Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67066-007-01</td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>ChiRhoClin, Inc</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>690679BD-A69A-A0CF-5C8A-E62D44A0CE6C</div>
<div>Set id: b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd</div>
<div>Version: 1</div>
<div>Effective Time: 20070803</div>
</div>
</div>Â <div class="DistributorName">ChiRhoClin, Inc</div></p>
</body></html>
